Pharma companies tone down ESG mentions, but not ambitions

Phar­ma com­pa­nies are scal­ing back the use of terms like “ESG” and “di­ver­si­ty, eq­ui­ty and in­clu­sion,” much like com­pa­nies in oth­er in­dus­tries.

In phar­ma 10-K fil­ings, men­tions of ESG, sus­tain­abil­i­ty, or di­ver­si­ty, eq­ui­ty and in­clu­sion (DE&I) dropped 15% in the first quar­ter of the year, com­pared to the same three months in 2023, ac­cord­ing to da­ta from Al­phaSense. Of the phar­ma an­nu­al fil­ings in the first three months of 2024, 65 men­tioned any of those terms, down from 76 dur­ing the same pe­ri­od last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.